BRIEF published on 06/18/2026 at 15:29, 2 months 25 days ago The Vanguard Group Discloses Position in Schroders plc Form 8.3 Takeover Code Schroders Plc Vanguard Group Stock Disclosure
BRIEF published on 06/18/2026 at 15:28, 2 months 25 days ago Vanguard Group Discloses Position in Picton Property Income Limited Takeover Code Securities Disclosure Vanguard Group Property Investment Picton Property
BRIEF published on 06/18/2026 at 15:28, 2 months 25 days ago Vanguard Group Discloses Position on JTC plc Form 8.3 Securities Disclosure Vanguard Group UK Takeover Code JTC Plc
PRESS RELEASE published on 06/18/2026 at 15:27, 2 months 25 days ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc The Vanguard Group, Inc. discloses 4.74% ownership in Tate & Lyle plc with 21,099,317 shares. Transactions include sales at 5.66 GBP and 5.69 GBP per unit Financial Transactions Vanguard Group Ownership Disclosure Stock Sales Tate & Lyle Plc
PRESS RELEASE published on 06/18/2026 at 15:26, 2 months 25 days ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc The Vanguard Group, Inc. discloses 3.59% stake in Spire Healthcare Group plc as of 17 June 2026. Details in Form 8.3 per Rule 8.3 of Takeover Code Form 8.3 The Vanguard Group Rule 8.3 Takeover Code Spire Healthcare Group Plc
BRIEF published on 06/18/2026 at 15:25, 2 months 25 days ago The Vanguard Group Discloses Positions in International Personal Finance plc Form 8.3 The Vanguard Group Takeover Code Stake Disclosure International Personal Finance
BRIEF published on 06/18/2026 at 15:24, 2 months 25 days ago The Vanguard Group Discloses Position in Gamma Communications plc Form 8.3 Vanguard Group Disclosures Equity Interest Gamma Communications
PRESS RELEASE published on 06/18/2026 at 15:24, 2 months 25 days ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc The Vanguard Group, Inc. discloses ownership of 2.57% of Schroders plc's 20p ordinary shares through Form 8.3 filing Form 8.3 The Vanguard Group Schroders Plc Ownership Disclosure 20p Ordinary Shares
BRIEF published on 06/18/2026 at 15:24, 2 months 25 days ago The Vanguard Group Discloses Position in Forward Industries Inc. Form 8.3 Disclosure Vanguard Group Shareholding Forward Industries
PRESS RELEASE published on 06/18/2026 at 15:23, 2 months 25 days ago Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited The Vanguard Group, Inc. discloses a 5.05% stake in Picton Property Income Limited as of 17 June 2026. Dealings include a sale of 2,920 securities at 0.70 GBP per unit Securities Vanguard Group Stake Disclosure Dealings Picton Property Income Limited
Published on 09/12/2026 at 02:35, 1 day 17 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 20 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 22 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 2 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 day 1 hour ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 12 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 21 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 21 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 days ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 12 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
